Physician profile
Crystal Hurst
NPI 1922508845
$4,934.71
in general payments reported to CMS, 2019-2025
25 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,047 · 2022: $2,146 · 2023: $401 · 2024: $1,068 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,140.60 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,072.61 | 2021-2025 | |
| Novo Nordisk INC | $663.35 | 2021-2025 | Ozempic |
| Glaxosmithkline, LLC. | $283.39 | 2022-2024 | Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.25 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $217.09 | 2022 | |
| Esperion Therapeutics, INC. | $208.86 | 2021 | |
| Lilly USA, LLC | $207.52 | 2021-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $198.09 | 2021-2023 | |
| Amgen INC. | $173.13 | 2022-2024 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $139.65 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $62.34 | 2022-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $51.37 | 2021 | |
| Pfizer INC. | $46.87 | 2021-2025 | |
| Corium, LLC | $45.55 | 2022-2025 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $28.46 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Gilead Sciences, INC. | $23.00 | 2023 | Epclusa |
| Phathom Pharmaceuticals, INC. | $21.52 | 2024 | Voquezna |
| Scilex Pharmaceuticals INC. | $18.04 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.42 | 2022 | |
| Shield Therapeutics INC | $13.35 | 2023 | Accrufer |
| Abbott Laboratories | $13.06 | 2021 | |
| Eisai INC. | $12.99 | 2021 | |
| Alkermes, INC. | $12.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.